Anzeige
Mehr »
Login
Sonntag, 24.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
265 Leser
Artikel bewerten:
(0)

Zhongchao Inc.: Zhongchao Inc. Reports the Fiscal Year 2020 Financial Results

Finanznachrichten News

SHANGHAI, April 30, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced its financial results for the fiscal year ended December 31, 2020.

Key Financial Highlights for the Fiscal Year 2020 as compared to the Fiscal Year 2019



For the Years Ended December 31,

($ millions, except per share data)

2020


2019


% Change

Revenues


$17.99


$14.88


20.9%

Gross profit


$11.87


$10.23


16.1%

Gross margin


66.0%


68.7%


-2.7 pp

Income from operations

$4.49


$3.64


23.3%

Operating margin


25.0%


24.5%


0.5 pp

Net income attributable to ordinary shareholders of
Zhongchao

$4.46


$4.05


10.2%

Earnings per share


$0.183


$0.187


-2.6%

* pp: percentage points





  • Revenues increased by 20.9% to $17.99 million for the fiscal year 2020, primarily due to the increasing orders for assistance services for patient-aid projects.
  • Gross profit increased by 16.1% to $11.87 million while gross margin decreased by 2.7 percentage points to 66.0% for the fiscal year 2020.
  • Operating income increased by 23.3% to $4.49 million for the fiscal year 2020, primarily due to the increased gross profit and partially offset by the increased operating expenses.
  • Net income attributable to the Company's ordinary shareholders increased by 10.2% to $4.46 million for the fiscal year 2020, primarily driven by the increased income from operations and partially offset by the increased income tax expenses.
  • Earnings per share was $0.183 for the fiscal year 2020, compared to $0.187 for last year.

Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "With revenues increasing by 20.9% to a record $17.99 million and operating income increasing by 23.3% to $4.49 million, our fiscal year 2020 financial results highlight continued strength in our businesses. Although our gross margin has a slight drawback, we expect to maintain a high-profit margin in the future for our reputation acknowledgment among leading pharmaceutical enterprises and non-for-profit organizations to design and produce high-quality professional content. In response to the outbreak of COVID-19, we, through our MDMOOC platform, have successfully developed and launched coronavirus curriculum with over 60 courses covering a wide range of medical specialties. In addition, our online courses increased 15% year-over-year in 2020. We are closely monitoring the fluid and uncertain situation of COVID-19, and we expect our revenues will continue to increase with the resume of work within China in the long-term."

Financial Results for the Fiscal Year Ended December 31, 2020

Revenues

For the fiscal year 2020, revenues increased by $3.11 million, or 20.9%, to $17.99 million from $14.88 million for last year. The increase in revenues was primarily due to the increasing orders for assistance services for patient-aid projects.

Cost of revenues

Cost of revenue increased by $1.46 million, or 31.4%, to $6.12 million for the fiscal year 2020 from $4.66 million for last year. The increase in the cost of revenues was driven by the increases in professional service fees and outsourced labor cost as we employed increasing outsourced staff with an increase in patient-aid projects.  

Gross profit

Gross profit increased by $1.65 million, or 16.1%, to $11.87 million for the fiscal year 2020 from $10.23 million for last year.

Gross margin decreased by 2.7 percentage points to 66.0% for the fiscal year 2020, compared to 68.7% for last year.  

Operating expenses

Selling and marketing expenses increased by $0.25 million, or 7.7%, to $3.44 million for the fiscal year 2020 from $3.20 million for last year. The increase in selling and marketing expenses was mainly attributable to the increase in advertising expenses to gain reputation in medical healthcare industry and the increase in salary and welfare to increase headcounts in selling and marketing department. As a percentage of total revenues, selling and marketing expenses was 19.1% for the fiscal year 2020, compared to 21.5% for last year.

General and administrative expenses increased by $0.60 million, or 23.8%, to $3.12 million for the fiscal year 2020 from $2.52 million for last year. The increase in general and administrative expenses was mainly attributable to the increase in salary and welfare expenses as a result of combining effects of an increase of headcounts in supporting functions; the increase in professional expenses since the Company became listed since February 2020; and the increase in writing off doubtful accounts against accounts receivable in accordance with the bad debt policy. As a percentage of total revenues, general and administrative expenses was 17.4% for the fiscal year 2020, compared to 17.0% for last year.  

Research and development expenses decreased by $0.05 million, or 5.5%, to $0.82 million for the fiscal year 2020 from $0.86 million for last year. As a percentage of total revenues, research and development expenses was 4.5% for the fiscal year 2020, compared to 5.8% for last year.  

Total operating expenses increased by $0.80 million, or 12.1%, to $7.38 million for the fiscal year 2020 from $6.58 million for last year. The increase in operating expenses was mainly attributable to the increased selling and marketing expenses and general and administrative expenses and partially offset by the decreased research and development expenses.

Operating income

Income from operations increased by $0.85 million, or 23.3%, to $4.49 million for the fiscal year 2020 from $3.64 million for last year. The increase in income from operations was primarily driven by the increased gross profit and partially offset by the increased operating expenses.

Operating margin increased by 0.5 percentage points to 25.0% for the fiscal year 2020 from 24.5% for last year.

Interest and other income, net

Interest income decreased by $0.07 million, or 30.5%, to $0.15 million for the fiscal year 2020 from $0.21 million for last year.

Other income, primarily consisted of government subsidies, was $0.31 for the fiscal year 2020, compared to $0.53 million for last year.

Income before income taxes

Income before income taxes increased by $0.55 million, or 12.6%, to $4.94 million for the fiscal year 2020 from $4.39 million for last year. The increase in income before income taxes was primarily attributable to the increased income from operations and partially offset by the decreased interest and other income.

Income tax expenses increased by $0.10 million, or 25.2%, to $0.49 million for the fiscal year 2020 from $0.39 million for last year.

Net income and EPS

Net income increased by $0.46 million, or 11.4%, to $4.46 million for the fiscal year 2020 from $4.00 million for last year. The increase in net income was primarily due to the increased income from operations and partially offset by the increased income tax expenses.

Net margin decreased by 2.1 percentage points to 24.8% for the fiscal year 2020 from 26.9% for last year.

After deducting for non-controlling interests, net income attributable to the Company's shareholders increased by $0.41 million, or 10.2%, to $4.46 million for the fiscal year 2020 from $4.05 million for last year.

Basic and diluted earnings per share was $0.183 for the fiscal year 2020, compared to $0.187 for last year. Weighted average number of shares outstanding was 24,425,637 for the fiscal year 2020, compared to 21,600,135 for last year.  

Financial Condition

As of December 31, 2020, the Company had cash, and cash equivalents of $15.07 million, compared to $7.83 million as of December 31, 2019. Accounts receivable were $10.32 million as of December 31, 2020, compared to $5.08 million as of December 31, 2019. Working capital was $26.61 million as of December 31, 2020, compared to $12.15 million as of December 31, 2019.

Net cash used in operating activities was $1.04 million for the fiscal year 2020, compared to net cash provided by operating activities of $1.41 million for last year. Net cash used in investing activities was $4.09 million for the fiscal year 2020, compared to $0.20 million for last year. Net cash provided by financing activities was $11.50 million for the fiscal year 2020, compared to net cash used in financing activities of $1.19 million for last year. 

Recent Business Highlights

  • In March 2021, renewing the contract with China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program "Pulmonary Arterial Hypertension Online Course - Connections with Famous Hospitals" in 2021.
  • In January 2021, co-sponsoring the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatment with China Association of Health Promotion and Education and Chinese Society of Liver Cancer.
  • In November 2020, expanding the scope of cooperation with Takeda Pharmaceutical in China to provide a broad range of services in medical editing, document collation, and medical training and education.

About Zhongchao Inc.

Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online provider of healthcare information, professional training and educational services to healthcare professionals under its "MDMOOC" platform (www.mdmooc.org) and to the public under its "Sunshine Health Forums" platform (www.ygjkclass.com) in China. The Company also offers patient management services under its "Zhongxun" platform (www.zhongxun.online). More information about the Company can be found at its investor relations website at http://izcmd.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company:
Pei Xu, CFO
Email: 
Phone: +86 21-3220-5987

Investor Relations:
Sherry Zheng 
Weitian Group LLC
Email:
Phone: +1 718-213-7386

ZHONGCHAO INC.

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(Expressed in U.S. dollar, except for the number of shares)




For the Years Ended
December 31,




2020



2019



2018


Revenues


$

17,989,788



$

14,882,763



$

12,865,870


Cost of revenues



(6,117,640)




(4,655,827)




(4,456,353)


Gross Profit



11,872,148




10,226,936




8,409,517















Operating Expenses













Selling and marketing expenses



(3,441,941)




(3,196,469)




(2,261,258)


General and administrative expenses



(3,124,301)




(2,524,003)




(1,425,663)


Research and development expenses



(816,553)




(864,320)




(1,447,949)


Total Operating Expenses



(7,382,795)




(6,584,792)




(5,134,870)















Income from Operations



4,489,353




3,642,144




3,274,647















Interest income, net



146,965




211,479




191,609


Other income, net



305,566




534,020




37,364


Income Before Income Taxes



4,941,884




4,387,643




3,503,620















Income tax expenses



(484,787)




(387,144)




(502,131)















Net Income



4,457,097




4,000,499




3,001,489















Net loss attributable to noncontrolling interests



1,283




46,171




17,834















Net Income Attributable to Zhongchao Inc.'s shareholders


$

4,458,380



$

4,046,670



$

3,019,323















Other Comprehensive Income (Loss)













Foreign currency translation adjustment



1,259,984




(173,604)




(379,520)


Comprehensive Income



5,717,081




3,826,895




2,621,969















Total comprehensive loss attributable to noncontrolling interests



1,283




46,171




17,834


Total comprehensive income attributable to Zhongchao Inc.'s
shareholders


$

5,718,364



$

3,873,066



$

2,639,803















Weighted average number of ordinary share outstanding













Basic and Diluted



24,425,637




21,600,135




20,764,245















Earnings per share













Basic and Diluted


$

0.183



$

0.187



$

0.145


ZHONGCHAO INC.

CONSOLIDATED BALANCE SHEETS

(Expressed in U.S. dollar, except for the number of shares)




December 31,
2020



December 31,
2019


ASSETS







Current Assets







Cash and cash equivalents


$

15,072,947



$

7,832,552


Short-term investments



2,032,928




-


Accounts receivable



10,321,837




5,078,419


Prepayments



554,298




325,496


Due from a related party



-




14,364


Other current assets



1,613,408




1,258,040


Total Current Assets



29,595,418




14,508,871











Investment in a limited partnership



1,258,787




-


Property and equipment, net



1,997,761




1,889,973


Deposit for property



700,884




-


Prepayments for lease of land



367,588




366,409


Intangible assets, net



34,973




37,323


Right of use assets



65,137




245,982


Deferred tax assets



795,547




688,994


Total Assets


$

34,816,095



$

17,737,552











LIABILITIES AND EQUITY









Current Liabilities









Accounts payable


$

408,426



$

117,064


Advances from customers



6,760




73,961


Deferred government grants, current portion



-




323,192


Income tax payable



1,523,175




897,892


Operating lease liabilities, current portion



62,160




210,219


Accrued expenses and other liabilities



981,433




735,334


Total Current Liabilities



2,981,954




2,357,662











Operating lease liabilities, noncurrent portion



-




41,363


Total Liabilities



2,981,954




2,399,025











Commitments and Contingencies


















Equity









Class A Ordinary Share (par value $0.0001 per share, 450,000,000 shares
    authorized; 19,435,423 and 16,102,420 shares issued and outstanding at
    December 31, 2020 and 2019, respectively)



1,944




1,610


Class B Ordinary Share (par value $0.0001 per share, 50,000,000 shares authorized;
    5,497,715 and 5,497,715 shares issued and outstanding at December 31, 2020
    and 2019, respectively)



550




550


Additional paid-in capital



22,775,154




12,044,855


Statutory reserve



801,502




415,813


Retained earnings



7,339,778




3,267,087


Accumulated other comprehensive income (loss)



915,213




(344,771)


Total Zhongchao Inc.'s Shareholders' Equity



31,834,141




15,385,144











Noncontrolling interests



-




(46,617)


Total Equity



31,834,141




15,338,527


Total Liabilities and Equity


$

34,816,095



$

17,737,552


ZHONGCHAO INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Expressed in U.S. dollar, except for the number of shares) 




For the Years Ended
December 31,




2020



2019



2018


Cash Flows from Operating Activities:













Net income


$

4,457,097



$

4,000,499



$

3,001,489


Adjustments to reconcile net income to net cash (used in) provided
    by operating activities:













Write off against accounts receivable



336,367




-




-


Depreciation and amortization expenses



202,325




102,905




38,699


Amortization of right of use assets



222,353




159,259




-


Recognition (reversal) of share-based compensation expenses



168,350




159,984




(14,483)


Deferred tax (benefits) expenses



(58,424)




(318,087)




60,975


Equity investment loss



25,622




-




-


Changes in fair value of short-term investments



10,331




-




-


Changes in operating assets and liabilities:













Accounts receivable



(5,486,914)




(3,134,065)




(792,031)


Prepayments



(197,402)




231,894




(583,613)


Other current assets



(1,143,200)




119,523




(659,145)


Accounts payable



260,350




94,461




(548,507)


Advances from customers



6,398




(476,261)




(125,872)


Income tax payable



535,981




618,120




296,904


Accrued expenses and other liabilities



179,738




408,725




85,954


Lease liabilities



(230,819)




(153,616)




-


Deferred government grants



(325,992)




(405,321)




552,277


Net Cash (Used in) Provided by Operating Activities



(1,037,839)




1,408,020




1,312,647















Cash Flows from Investing Activities:













Purchases of property and equipment



(160,602)




(1,312,941)




(668,067)


Payments of deposits for property purchase



(688,267)




-




-


Payment for land use rights



-




-




(418,520)


Investments in short-term investments



(2,043,259)




(2,460,879)




(2,920,260)


Investment in a limited partnership



(1,217,039)




-




-


Release from short-term investments



-




3,618,940




3,502,799


Buy out of a non-controlling interests



-




(33,718)




-


Loan repayment from (provided to) a related party



14,489




(14,476)




-


Net Cash Used in Investing Activities



(4,094,678)




(203,074)




(504,048)















Cash Flows from Financing Activities:













Proceeds from issuance of common stocks in connection with
    initial public offering, net of offering cost



11,886,363




-




-


Payment of expenses relating to initial public offerings



(388,709)




(468,328)




-


Capital contribution from shareholders



-




-




3,580,260


Proceeds from bank borrowings



-




-




756,544


Repayment of bank borrowings



-




(723,788)




-


Net Cash Provided by (Used in) Financing Activities



11,497,654




(1,192,116)




4,336,804















Effect of exchange rate changes on cash and cash equivalents



875,258




(98,953)




(205,243)















Net increase (decrease) in cash and cash equivalents



7,240,395




(86,123)




4,940,160


Cash and cash equivalents at beginning of year



7,832,552




7,918,675




2,978,515


Cash and cash equivalents at end of year


$

15,072,947



$

7,832,552



$

7,918,675















Supplemental Cash Flow Information













Cash paid for interest expense


$

-



$

30,312



$

5,840


Cash paid for income tax


$

2,642



$

87,111



$

144,252















Noncash investing activities













Right of use assets obtained in exchange for operating lease
    obligations


$

37,919



$

419,362



$

-


SOURCE Zhongchao Inc.

© 2021 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.